A Study of LY900027 Given by Insulin Pump to Participants With Type 1 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 1 Interventions:   Drug: LY900027;   Drug: Insulin Lispro Sponsor:   Eli Lilly and Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Funding Opportunity RFA-DK-19-022 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits U01 applications for the establishment of a clinical consortium, composed of one Data Coordinating Center (DCC) and up to 10 Clinical Centers (CC), to conduct studies on diabetes mellitus, with an emphasis on Type 1 diabetes (T1D), that occurs after or as a consequence of one or more episodes of acute pancreatitis. The Consortium will form multi-disciplinary teams composed of members from the CCs and DCC to undertake a prospective longitudinal observational study of the occurrence of diabetes...
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
Funding Opportunity RFA-DK-19-023 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits U01 applications for the establishment of a clinical consortium, the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC), composed of one Data Coordinating Center (DCC) and up to 10 Clinical Centers (CC), to conduct studies on Type 1 diabetes mellitus (T1D) that occurs after or as a consequence of one or more episodes of acute pancreatitis. Applications for the Clinical Centers (CC) are submitted in response to a separate FOA: RFA-DK-19-022: Type 1 Diabetes in Acute Pancreatitis Consort...
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
This study compared the pharmacokinetic and glucodynamic profiles, safety, and tolerability of URLi and lispro (Humalog®) in Japanese patients with type 1 diabetes mellitus (T1DM).MethodsThis was a phase 1, single center, randomized, patient ‐ and investigator‐blind, 2‐period, crossover study. Thirty‐one patients received a single subcutaneous 15‐U dose of URLi or lispro before undergoing a euglycemic clamp procedure. Primary pharmacokinetic endpoints: time to early half‐maximal drug concentration (early 50% tmax) and area under the concentration versus time curve from 0 to 30 minutes (AUC[0 ‐30min]))}) p...
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Glycemic control in type 1 diabetes mellitus (T1DM) remains a challenge for many, despite the availability of modern diabetes technology. While technologies have proven glycemic benefits and may reduce excess mortality in some populations, both mortality a...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Conclusions: Our estimated rates of prevalence of GP in T1DM and T2DM indicate that GP is not a common clinical complication in these populations. Majority of EMRs that indicated a diagnosis of GP did not include any documentation of definitive diagnostic testing (EGD and/or GES).
Source: Journal of Clinical Gastroenterology - Category: Gastroenterology Tags: ALIMENTARY TRACT: Original Articles Source Type: research
AbstractSodium-glucose cotransporter 2 (SGLT2) inhibitor clinical studies in type 1 diabetes mellitus (T1DM) have demonstrated reduced HbA1c and lower glucose variability with increased time in optimal glucose range as well as additional benefits of reductions in weight and insulin dose without increasing the incidence of hypoglycaemia. However, the appropriate use of SGLT2 inhibitor therapies within clinical practise to treat people with T1DM remains unclear. In this article we have used consensus expert opinion alongside the available evidence, product indication and most recent clinical guidance to provide support for t...
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
Nature Reviews Gastroenterology &Hepatology, Published online: 06 December 2019; doi:10.1038/s41575-019-0242-7An area of research suggests a role for microbiota in the pathogenesis of pancreatic diseases, such as pancreatitis, pancreatic cancer and type 1 diabetes mellitus. In this Perspectives, the authors examine the literature implicating microorganisms in diseases of the pancreas as well as the evidence of an inherent pancreatic microbiota.
Source: Nature Reviews Gastroenterology and Hepatology - Category: Gastroenterology Authors: Source Type: research
ConclusionIncreased expression levels of KISS1 and KISS1R in case of diabetes mellitus may play a role in the altered placentation process and lead to the development of preeclampsia.
Source: Archives of Gynecology and Obstetrics - Category: OBGYN Source Type: research
In this study, we investigated whether DIM could improve insulin-dependent diabetes and nephropathy in streptozotocin (STZ)-induced diabetic mice. In mice, STZ induced hyperglycemia, hunger, thirst, and abnormally increased kidney weight and serum creatinine, which is a renal functional parameter. DIM decreased STZ-increased high blood glucose levels and food and water intake in diabetic mice. DIM also improved diabetic nephropathy by inhibiting the expression of PKC-α, the marker of albuminuria, and TGF-β1, an indicator of renal hypertrophy, in diabetic mice. Our findings suggest that DIM may ameliorate...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
More News: Diabetes | Diabetes Mellitus | Diabetes Type 1 | Endocrinology | Insulin | Research | Study